Amplia enters clinical collaboration with Eli Lilly to test narmafotinib plus Lilly’s KRAS G12C inhibitor olomorasib in non-small cell lung cancer

Amplia said it has executed a Clinical Trial Collaboration and Supply Agreement, or CTCSA, with Eli Lilly, under which the two companies will evaluate Amplia’s investigational FAK inhibitor narmafotinib in combination with Eli Lilly’s KRAS G12C inhibitor olomorasib in non-small cell lung cancer.

According to the announcement distributed via Yahoo Finance, the collaboration is structured as a clinical trial partnership, with the companies also addressing supply arrangements through the CTCSA. The statement frames narmafotinib as the investigational component from Amplia, while olomorasib is Lilly’s investigational therapy designed to target KRAS G12C-driven indicating.

KRAS is a gene that can be altered in many cancers, and the G12C variant is one of the best-studied KRAS mutations in drug development. KRAS G12C inhibitors are designed to bind the KRAS protein when it is in its specific inactive form, with the goal of suppressing downstream indicating that supports tumor growth. FAK, or focal adhesion kinase, is another indicating target linked to how some cancers grow and spread. The combination approach reflects an effort to potentially disrupt cancer biology from two angles, KRAS-driven pathways and FAK-related indicating.

The companies’ trial plan, as described in the Yahoo Finance item, is focused on non-small cell lung cancer, a major lung cancer category that includes multiple molecular subtypes. While Lilly already has an established commercial presence for its KRAS G12C inhibitor in eligible patient populations, this new effort is presented as an evaluation of olomorasib together with narmafotinib rather than a stand-alone therapy.

Eli Lilly’s involvement underscores the competitive and collaborative push across the oncology sector toward combination regimens. For drug developers, adding a second mechanism can be a way to improve depth or duration of response, address resistance pathways, and potentially expand the set of patients who benefit. For smaller biotech firms like Amplia, pairing with a large partner can also help secure development infrastructure and supply capabilities necessary to run combination trials.

Still, the announcement did not provide several details that investors and clinicians typically look for. The Yahoo Finance-distributed item does not spell out the trial’s phase, enrollment size, primary endpoints, eligibility criteria, geographic scope, or timing for readouts. It also does not disclose any financial terms, milestone payments, or how responsibilities are divided between the parties beyond the overall collaboration and supply agreement structure.

The disclosure is also limited on what specific biomarker strategy will be used, beyond the stated disease area and combination components. For example, the statement does not clarify whether inclusion will be restricted to KRAS G12C mutations and how FAK pathway activity might be assessed, if at all. Without those particulars, it is not possible to gauge how the study’s design could influence interpretability or regulatory relevance.

Looking ahead, the near-term catalyst for this collaboration would be any subsequent disclosure of protocol details once trial initiation approaches, including the intended patient population and the endpoints the companies plan to use to assess whether narmafotinib and olomorasib together offer superior activity compared with relevant baselines. More information on trial timeline and interim analyses, when released by the companies, will be important for tracking progress.